Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors
Benzinga Newsdesk 1 week ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagersFavorable safety profile, with
- Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagers
- Favorable safety profile, with new data indicating healthy tissues expressing either TAA remain intact
- Attractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and EpCAM
